maradon 333 /
25 November 2016Americas

Novartis acquires Selexys Pharmaceuticals

Novartis has acquired Selexys Pharmaceuticals Corporation, a company specialising in the development of therapeutics in certain hematologic and inflammatory disorders.

The acquisition followed a study in which the use of SelG1, an antibody, was evaluated in the reduction of pain amongst patients with sickle cell disease.

Terms of the deal could total up to $665 million in upfront, acquisition and milestone payments, according to a statement from Novartis.

Bruno Strigini, CEO of Novartis Oncology, said: "Sickle cell disease affects millions of people around the world and there are limited therapies available for treatment of vaso-occlusive pain crises, a very common complication of the disease."

He added: “With this acquisition, Novartis is able to leverage its leadership in hematology research to advance development of a potential new treatment option for patients living with this debilitating condition.”

Novartis had obtained the exclusive right to acquire Selexys and SelG1 in 2012.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at